

InEurHeart

Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia

Frederic Sacher¹, Tobias Reichlin², Mathieu Le Bloa³, Gregoire Massoulie⁴, Xavier Waintraub⁵, Philippe Maury⁶, Daniel Scherr⁷, Romain Tixier¹, Benoit Guy-Moyat⁸, Josselin Duchateau¹, Christian Meyer⁹, Maxime Sermesant¹⁰, Melanie Gunawardene¹¹, Noemie Bronnec¹, Aurore Georget¹², Sanna Azzouz¹³, Estelle Gandjbakhch⁵, Nicolas Derval¹, Michel Haissaguerre¹, Roland Tilz¹⁴, Mélèze Hocini¹, Thomas Deneke¹⁵, Thomas Pambrun¹, Maureen Rutten-van Molken¹³, Helmut Pürerfellner¹⁶, Florian Englert¹⁷, Elena Sauer¹⁵, Pierre Jais¹, Antoine Benard¹², Hubert Cochet¹

1. IHU LIRYC - CHU/Univ Bordeaux, Pessac, France; 2. Inselspital Bern, Bern, Switzerland; 3. CHU Vaudois, Lausanne, Switzerland; 4. CHU de Clermont-Ferrand, Clermont-Ferrand, France; 5. Pitié-Salpêtrière University Hospital, Paris, France; 6. HOPITAL RANGUEIL TOULOUSE, Toulouse, France; 7. Medical University of Graz, Austria, Graz, Austria; 8. CHU Limoges, Limoges, France; 9. Division of cardiology, EVK Düsseldorf, Düsseldorf, Germany; 10. Université Côte d'Azur, Inria Epione Team, Sophia Antipolis, France; 11. Asklepios center, Hamburg, Germany; 12. USMR, pôle de santé publique, CHU de Bordeaux, Bordeaux, France; 13. Erasmus School of Health policy and Management (ESHPM), Erasmus University Rotterdam, The Netherlands; 14. Department of Rhythmology, German Center for Cardiovascular Research (DZHK), Lübeck, Germany; 15. Rhönklinikum Campus, Bad Neustadt, Germany; 16. Ordensklinikum Linz Elisabethinen, Linz, Austria; 17. German Heart Center, München, Germany.



NCT: 05225935



Funded by the
European Union




VT ablation



Conventional VT ablation


Identification of targets with invasive catheter mapping owing to operator experience



- No images
- Free to use any catheters/strategy
- Final endpoint > non-inducibility

CT-guided VT ablation

Identification of targets with non-invasively with CT-Scan and inHEART modelization



- Merging
- Ablation of isthmii identified by CT-Scan (40-50W with at least 10g & ≥ 45 sec)
- Inducibility when all isthmii have been targeted > if inducible > target the VT

▪ Main objective:

To compare conventional vs CT-guided VT ablation strategy in term of procedure duration, efficacy, safety and cost

Methods




Institutional multicentric, prospective, single-blinded randomized clinical trial,
Funded by EIT-Health.



113 patients



14 Clinical sites



France:

- ✓ Bordeaux University Hospital (Pr. Frédéric Sacher)
- ✓ Toulouse University Hospital (Pr. Philippe Maury)
- ✓ Clermont-Ferrand University Hospital (Dr. Grégoire Massoulié)
- ✓ Paris University Hospital (Dr. Xavier Waintraub)
- ✓ Limoges University Hospital (Dr. Benoît Guy-Moyat)

Germany:

- ✓ Rhön-Klinikum AG, Bad Neustadt (Pr. Thomas Deneke)
- ✓ Evangelisches Krankenhaus Düsseldorf (Pr. Christian Meyer)
- ✓ Technical University of Munich (TUM) (Pr. Isabel Deisenhofer)
- ✓ Asklepios Kliniken Hamburg GmbH (Pr. Stephan Willem)
- ✓ Universitäres Herzzentrum Lübeck (Pr. Roland Tilz)

Austria:

- ✓ Medical University of Graz (Pr. Daniel Scherr)
- ✓ Ordensklinikum Linz GmbH (Pr.Dr. Helmut Pürerfellner)

Switzerland:

- ✓ Inselspital Bern (Pr. Tobias Reichlin)
- ✓ Vaudois University Hospital, Lausanne (Dr. Mathieu Le Bloa)

inEurHeart Workflow




Inclusion criteria

- Indication for de-novo VT ablation
- Prior myocardial infarction
- Presence of an implantable cardioverter defibrillator, or planned ICD implantation before discharge
 - And
- At least one of the following monomorphic VT events within the last 6 months:

- A: ≥3 episodes of VT treated with antitachycardia pacing (ATP),
- B: ≥1 appropriate ICD shocks,
- C: sustained VT below detection rate of the ICD documented by ECG or any cardiac monitor,
- D: Sustained VT recorded on 12 leads ECG in the absence of ICD

Exclusion criteria

- Active myocardial ischemia
- Intra-cardiac thrombus
- Absence of MI substrate
- Mechanical aortic or mitral valve
- Prior VT ablation
- Polymorphic VT or VF as presenting arrhythmia
- Renal failure (Creatinine clearance <30 mL/min)
- NYHA Functional class IV heart failure
- Systemic illness likely to limit survival to <1 year



inEurHeart Workflow – CT guided arm




- Importing images
- Merging
- Ablation of the identified isthmus
- EP Study

If negative: stop there

If positive: map and ablate the induced VT



inEurHeart – Flowchart



inEurHeart – Baseline population



	Conventional VT ablation (n=56)	CT-guided VT ablation (n=57)
Age – years, mean ±SD	65.4 ±9.1	63.8 ±8.5
Male – no. (%)	50 (89.3)	53 (93.0)
BMI, mean ±SD	27.8 ±4.0	29.6 ±4.9
Diabetes– no. (%)	21 (39.6)	25 (43.9)
HTA - no. (%)	36 (67.9)	35 (61.4)
History of stroke/TIA – no. (%)	6 (11.3)	5 (8.8)
History of AF or A Flutter – no. (%)	12 (22.6)	14 (24.6)
CHADS-VASc risk score – mean, ±SD	3.4 ±1.7	3.3 ±1.2
Duration since myocardial infarction, months - mean, ±SD	183.6 ±126.7	165.1 ±125.8
Prior cardiac arrest – no. (%)	7 (13.2)	14 (24.6)
LVEF – %, mean, ±SD	34.5 ±11.2	35.2 ±11.4
History of electrical storm – no. (%)	23 (41.8)	21 (36.8)
Amiodarone use – no. (%)	31 (55.4)	35 (61.4)
Dysthyroisism – no. (%)	7 (13.2)	11 (19.3)

InEurHeart – Procedure



	Conventional VT ablation (n=56)	CT-guided VT ablation (n=57)
General anesthesia – no. (%)	21 (38.9)	21 (40.4)
Use of high density mapping catheter – no. (%)	51 (91.1)	14 (25.5)
Contact Force ablation catheter – no. (%)	51 (91.1)	52 (91.2)
Number of anatomical isthmus identified on CT– mean, \pm SD	2.9 \pm 1.3	3.2 \pm 1.3
Non inducibility after CT ablation – no. (%)	NA	43 (75.4)
Any VT inducible at the end of the procedure – no. (%)	16 (33.3)	8 (17)
X-ray Duration (min)	12.8 \pm 9.6	12.5 \pm 13.1
Total RF duration – mean, \pm SD	36.6 \pm 19.5	44.4 \pm 19.4
Major AE (grade 3≤) related to the procedure	2 (3.6)	1 (1.8)

InEurHeart – primary endpoint



Procedure duration definition:


Time between first catheter introduction to last RF application

	Total (n=113)	Conventional VT ablation (n=56)	CT guided VT ablation (n=57)	Adjusted percentage difference
Mean procedure duration in ITT in min (SD)	134.4 (52.0)	148.8 (50.6)	120.3 (49.8)	-19.1% [-31.7 ; -6.6] p=0.0027
Mean procedure duration per protocole in min (SD)	129.3 (49.7)	148.8 (50.6)	107.1 (38.3)	-28.0% p<.0001


InEurHeart – secondary endpoints



	Total (n=113)	Conventi- onal VT ablation (n=56)	CT guided VT ablation (n=57)	Stat
Absence of recurrence at one year (ITT)	80 (72.1%)	37 (67.3%)	43 (76.8%)	+ 9.5% NS
Absence of recurrence at one year (per-protocol) with CF catheter	74/101 (73.3%)	33/50 (66.0%)	41/51 (80.4%)	+ 14.4% NS



InEurHeart – secondary endpoints



Procedural cost

- in french public health system
- without GA
- without housing
- assuming a cost for image modelisation €1250

	Conventional	CT guided	Adjusted difference
Personal cost	€ 545,17	€ 392,39	€ 152,78
Material cost	€ 5 562,82	€ 5 069,90	€ 492,92
Total cost	€ 6107,99	€ 5462,29	€ 645,7 (-10.6%)

* Events of interest = Unplanned hospitalizations due to cardiac reasons, cardiovascular-related death and VT events






Conclusions



Digital twin of the infarct scar based on cardiac CT scan to guide VT ablation allows:

- **A reduction of procedure duration by 19% (28% when the protocol was followed)**
- **Without increased procedural risk**
- **With a one year VT free rate of 76.8% vs 67.3% in the conventional group (NS)**
- **Procedural cost reduced by 10% in the CT-guided group.**

Acknowledgement to the participating clinical sites



Thank you



Prof. Roland TILZ
Dr. Christian HEEGER
Dr. Sorin POPESCU
Dr. Bettina KIRSTEIN
Jordanka NACEVA
Claudia BREITHAUPT
Alexandra KAZUBSKI
Mirco KÜCHLER



Prof. Daniel SCHERR
Dr. Ursula ROHRER
Dr. Martin MANNINGER
Lucia ANDRECS
Corinna MAGG
Nina THONHOFER